These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21091860)

  • 1. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
    Small CB; Margolis DA; Shaefer MS; Ross LL
    BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
    Dart Trial Team
    Trop Med Int Health; 2008 Jan; 13(1):6-16. PubMed ID: 18290996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.
    Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F
    Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis.
    Tangamornsuksan W; Lohitnavy O; Kongkaew C; Chaiyakunapruk N; Reisfeld B; Scholfield NC; Lohitnavy M
    J Pharm Pharm Sci; 2015; 18(1):68-76. PubMed ID: 25877443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 18. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of abacavir hypersensitivity by ELISpot method.
    Esser S; Jablonka R; Heinemann FM; Reuter S; Jaeger H; von Krosigk A; Schenk-Westkamp P; Schadendorf D; Horn PA; Lindemann M
    Inflamm Allergy Drug Targets; 2012 Jun; 11(3):227-34. PubMed ID: 22338581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.